New Hope for Infant Seizures: Nitrazepam Trial Shows Promise

A recent clinical trial conducted at the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh has identified nitrazepam as a potential new treatment for infantile epileptic spasms syndrome (IESS) that is resistant to existing therapies. The study, titled the NitRIS Trial, focused on children aged six to 30 months who had not responded to corticosteroids and vigabatrin, the typical first-line treatments for IESS. In the trial, 40 children were divided into two groups. Eleven of the 20 children treated with nitrazepam experienced a complete cessation of spasms for at least four weeks. In contrast, only three of the 20 children receiving topiramate achieved the same outcome. Furthermore, nine children on nitrazepam achieved electroclinical remission, meaning abnormal brain activity also resolved, compared to only two on topiramate. Quality-of-life scores also favored nitrazepam. The researchers described these results as proof-of-concept evidence, noting that nitrazepam is an oral medicine that is relatively inexpensive and widely available. However, they emphasized that larger studies with longer follow-up periods are necessary to confirm these benefits, assess long-term development, and ensure safety, particularly as the results may not apply to children with genetic causes for their condition.

The temporal anchor for this report is 2026-10-18T18:28:08+00:00. The research study was conducted prior to this date, and its findings were internationally recognized two days before the temporal anchor. The trial itself involved assessing outcomes after 10 weeks, indicating the research was completed in the recent past relative to the anchor date. Future research, including larger studies with longer follow-up, is still needed to establish long-term benefits.